Multimodal drug for patients after stroke: novel modalities

Interview with Professor Michael Brainin, MD, PhD, President of the World Stroke Organization (Austria)

Strong evidences clearly demonstrate the efficacy of Cerebrolysin, a well-studied drug, in patients after stroke. Cerebrolysin a neurorecovery stimulating compound with neuroprotective properties. Ongoing clinical studies uncover new effects and horizons of its use. Currently undergoing a clinical study of the 4th phase, which will determine the place of Cerebrolysin in routine practice. The Professor Michael Brainin (Austria), the President of World Stroke Organization, had been kind enouth to tell us about multimodal effects of Cerebrolysin, future studies, and its prospective use.